Page last updated: 2024-11-06

lysergic acid diethylamide and Depressive Disorder, Major

lysergic acid diethylamide has been researched along with Depressive Disorder, Major in 9 studies

Lysergic Acid Diethylamide: Semisynthetic derivative of ergot (Claviceps purpurea). It has complex effects on serotonergic systems including antagonism at some peripheral serotonin receptors, both agonist and antagonist actions at central nervous system serotonin receptors, and possibly effects on serotonin turnover. It is a potent hallucinogen, but the mechanisms of that effect are not well understood.
lysergic acid diethylamide : An ergoline alkaloid arising from formal condensation of lysergic acid with diethylamine.

Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)

Research Excerpts

ExcerptRelevanceReference
"Our search revealed 12 eligible studies (n = 257; 124 healthy participants, and 133 patients with mood disorders), with data from randomized controlled trials involving psilocybin (n = 8), lysergic acid diethylamide ([LSD]; n = 3), and ayahuasca (n = 1)."5.12Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants. ( de Manincor, M; Galvão-Coelho, NL; Gonzalez, M; Marx, W; Perkins, D; Sarris, J; Sinclair, J, 2021)
"Psychedelic therapy shows promise for Major Depressive Disorder, especially when treatment-resistant, as well as life-threatening illness distress."3.01Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis. ( Cleare, AJ; Ko, K; Kopra, EI; Rucker, JJ, 2023)
"Chronic pain is a leading cause of disability, reduced productivity, healthcare seeking behavior, and a contributor to opioid overdose in the United States."3.01Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs. ( Baumann, MH; Belouin, SJ; Berger, A; Dworkin, RH; Ghauri, MH; Hendricks, PS; Henningfield, JE; Lanier, RK; Ross, S; Zia, FZ, 2023)
"Recent trials with psychedelics in major depressive disorder and treatment-resistant depression showed remarkable improvements in depressive symptoms that can last for up to several months after even a single administration."1.72How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework. ( Hillhouse, TM; Magaraggia, I; Porter, JH; Schreiber, R; van den Berg, M, 2022)

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19901 (11.11)18.7374
1990's0 (0.00)18.2507
2000's1 (11.11)29.6817
2010's0 (0.00)24.3611
2020's7 (77.78)2.80

Authors

AuthorsStudies
Han, B1
Blanco, C1
Einstein, EB1
Compton, WM1
van den Berg, M1
Magaraggia, I1
Schreiber, R1
Hillhouse, TM1
Porter, JH1
Yang, KH1
Han, BH1
Palamar, JJ1
Ko, K1
Kopra, EI1
Cleare, AJ1
Rucker, JJ1
Zia, FZ1
Baumann, MH1
Belouin, SJ1
Dworkin, RH1
Ghauri, MH1
Hendricks, PS1
Henningfield, JE1
Lanier, RK1
Ross, S1
Berger, A1
Galvão-Coelho, NL1
Marx, W1
Gonzalez, M1
Sinclair, J1
de Manincor, M1
Perkins, D1
Sarris, J1
Schmid, Y1
Gasser, P1
Oehen, P1
Liechti, ME1
El Khoury, A1
Johnson, L1
Aberg-Wistedt, A1
Stain-Malmgren, R1
Shagass, C1
Straumanis, JJ1

Reviews

4 reviews available for lysergic acid diethylamide and Depressive Disorder, Major

ArticleYear
Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis.
    Journal of affective disorders, 2023, 02-01, Volume: 322

    Topics: Depression; Depressive Disorder, Major; Hallucinogens; Humans; Lysergic Acid Diethylamide; Psilocybi

2023
Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs.
    Neuropharmacology, 2023, 08-01, Volume: 233

    Topics: Chronic Pain; Depressive Disorder, Major; Hallucinogens; Humans; Lysergic Acid Diethylamide; Psilocy

2023
Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants.
    Psychopharmacology, 2021, Volume: 238, Issue:2

    Topics: Affect; Banisteriopsis; Depression; Depressive Disorder, Major; Double-Blind Method; Hallucinogens;

2021
Evoked potentials and psychopathology.
    Proceedings of the annual meeting of the American Psychopathological Association, 1969, Volume: 58

    Topics: Adjustment Disorders; Age Factors; Attention; Auditory Cortex; Bipolar Disorder; Brain Diseases; Com

1969

Other Studies

5 other studies available for lysergic acid diethylamide and Depressive Disorder, Major

ArticleYear
Mental health conditions and receipt of mental health care by illicit lysergic acid diethylamide (LSD) use status among young adults in the United States.
    Addiction (Abingdon, England), 2022, Volume: 117, Issue:6

    Topics: Adolescent; Adult; Cross-Sectional Studies; Depressive Disorder, Major; Humans; Lysergic Acid Diethy

2022
How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework.
    Psychopharmacology, 2022, Volume: 239, Issue:6

    Topics: Antidepressive Agents; Depressive Disorder, Major; Hallucinations; Hallucinogens; Humans; Lysergic A

2022
Past-year hallucinogen use in relation to psychological distress, depression, and suicidality among US adults.
    Addictive behaviors, 2022, Volume: 132

    Topics: Adult; Depression; Depressive Disorder, Major; Hallucinogens; Humans; Lysergic Acid Diethylamide; N-

2022
Acute subjective effects in LSD- and MDMA-assisted psychotherapy.
    Journal of psychopharmacology (Oxford, England), 2021, Volume: 35, Issue:4

    Topics: Adult; Combined Modality Therapy; Compassionate Use Trials; Consciousness Disorders; Depressive Diso

2021
Effects of long-term lithium treatment on monoaminergic functions in major depression.
    Psychiatry research, 2001, Dec-15, Volume: 105, Issue:1-2

    Topics: Adult; Aged; Bipolar Disorder; Blood Platelets; Carrier Proteins; Depressive Disorder, Major; Female

2001